RxDoctor Payments Data

Sheri Smith

Family · Newark, DENPI 1265833354

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 22 payments — averaging $72.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$525
  • Novo Nordisk$242
  • Kyowa Kirin, Inc.$230
  • GSK$147
  • AbbVie$125
  • Phathom Pharmaceuticals, Inc.$123
  • plus $199 from 3 others

What the payments were for

  • Food & beverage$1,591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,591 in reported general payments places this provider in the 70th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$155,819
Medicare patients
477
Services billed
1,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$60,130
EliquisApixaban26$42,057
XareltoRivaroxaban28$36,338
JardianceEmpagliflozin19$31,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,936
FarxigaDapagliflozin Propanediol12$15,609
Rosuvastatin Calcium238$5,992
Atorvastatin Calcium294$3,936
Metoprolol Succinate112$2,296
Omeprazole134$2,205
Levothyroxine Sodium183$1,906
Valsartan33$1,809
Lisinopril203$1,625
Amlodipine Besylate181$1,593
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide27$1,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$242$60,13024 claims
Johnson & JohnsonXarelto$55$36,33828 claims
GSKTrelegy Ellipta$147$16,93613 claims
AstraZenecaFarxiga$525$15,60912 claims
AbbVieSynthroid$125$1,33732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 523 family providers in Delaware.

Other family in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →